Showing posts with label options. Show all posts
Showing posts with label options. Show all posts

Sunday, August 5, 2012

Options Increasing for Coping With Kids' Food Allergies

AppId is over the quota
AppId is over the quota
By Serena Gordon
HealthDay Reporter

FRIDAY, Aug. 3 (HealthDay News) -- Kids with a serious food allergy generally have to steer clear of the offending food, but methods now under development could change that common scenario.

More than 3 million American youths -- about one of every 25 -- have a food allergy of some sort, usually to milk, eggs or peanuts, according to U.S. government statistics. For them, "avoidance has been the mainstay of treatment for a long time," said Dr. William Silvers, an allergist in private practice in Vail, Colo., and a spokesman for the American College of Allergy, Asthma and Immunology.

"Now what we're seeing is an increased interest in oral immunotherapy," Silvers said. "This means giving small and slowly increased doses orally of foods that children are allergic to, and building up the amount ingested over time to desensitize the child to the food so they can tolerate it."

That doesn't come string-free, though. Dr. Carla Davis, an allergist at Texas Children's Hospital in Houston, noted that once children have been desensitized to a certain food, they have to continue eating it regularly or they'll become allergic to the food again.

"There isn't a maintenance of tolerance if you avoid the foods," she explained.

Along with desensitization, another potential new treatment for food allergies is a drug called omalizumab (Xolair). Silvers said that it works by blocking the activity of the allergy-causing substance known as immunoglobulin E (IgE) so that an allergic reaction never starts.

However, the food allergy would come back if a person were to stop using the drug, which is currently available only in an injectable form and has not been approved by the U.S. Food and Drug Administration for use in children younger than 12.

Some researchers, though, think that a combination of the two treatments might be better than either alone. Early reports from a very small study found that nine of 11 children who were given Xolair and then desensitized to milk were able to consume up to 12 ounces of dairy a day without a reaction.

Davis said that researchers also are testing herbal formulations and that one particular combination of nine herbs was able to prevent a serious allergic reaction, known as anaphylaxis, in mice. "It's another one of the treatments that may be up-and-coming," she said, though there's no evidence in humans yet.

What has been proven true, though, is that many kids simply outgrow their food allergies, even some of the most deadly ones. Davis said that as many as one in five youngsters may outgrow an allergy to peanuts but that allergies to eggs, milk, soy and wheat are most often outgrown. In general, peanuts, tree nuts and seafood allergies tend to stay with children as they grow, she said.

To know whether a child has outgrown a food allergy requires repeated skin and blood tests, Silvers said. "If IgE levels in the blood decrease over time, or if skin testing comes back negative or a very small reaction, a child or adult can be given a food challenge to see if they'll react," he said.

To be safe, though, the testing "must be done under a physician's supervision," Davis said, because a serious reaction could occur if the youngster has not outgrown the allergy.

For kids with lingering food allergies, Silvers recommended that the child or parent always carry the antihistamine Benadryl and an epinephrine injection pen. If it's suspected that the child accidentally ingested an allergy-inducing food, the youngster should take the antihistamine right away. If the allergic reaction worsens, administer the epinephrine and get to an emergency room as quickly as possible.

It's important to go to the hospital after a serious allergic reaction, Davis said, because there can be a second wave to the reaction about four to six hours later.

Many children have their own epinephrine pens at their school nurse's office. In Chicago, the public school system recently decided to take the next step and keep a supply of epinephrine pens in every school, and train school personnel in their use, so that they're prepared for any serious allergic reactions.

"This is a good idea because about one in five children have their first serious reaction in school," Davis said.

For those living with food allergies, Davis said, it's important to find a balance between being vigilant and being overanxious. Parents should be "prepared for a reaction, but shouldn't expect one all the time," she said. "Some parents become extremely anxious about the contact their child may have with food. Health vigilance is important, but so is quality of life."

MedicalNewsCopyright © 2012 HealthDay. All rights reserved. SOURCES: Carla Davis, M.D., assistant professor, pediatrics, section of allergy and immunology, department of pediatrics, Texas Children's Hospital, Houston; William Silvers, M.D., allergist, Allergy Asthma Colorado, Vail, Colo.



View the original article here

Sunday, July 8, 2012

Boston Globe opinion piece on decision aids for dying patients on end-of-life care options

Angelo Volandes, MD, a physician at Massachusetts General Hospital, wrote an opinion piece published in the Boston Globe today.  He tells the story of a patient dying of cancer, with whom he brought up the topic of end-of-life care options:

“For the next hour I introduced a vocabulary as foreign to her as spondee and trochee were to me. Life-prolonging treatment and CPR, ventilators and intubation, DNR and DNI — terms that she would need to learn quickly. Unfortunately, I was trying to teach her a new lexicon in the midst of the haze of nausea and hospitalization.

Dazed and confused, they looked at me blankly. Words often fail us in medicine. How could I explain these abstract ideas and treatments? Most patients think hospitals and medical interventions look like what they see on television where most survive CPR beautifully; the truth is most people with advanced incurable cancer do not do well with these interventions and often suffer at the end of life.

Finally, I tried a different approach. “Do you mind if we take a walk through the ICU?” I said.

If words failed me, perhaps seeing the intensive care unit would help. Seated in a wheelchair …Helen got a tour of the ICU, where she saw an intubated patient on a ventilator and a patient having a large intravenous line placed. Her decision-making would be informed by what she saw, instead of having to imagine what my terms really meant.

When we arrived back at her room, she looked at me and said, “Words, words, words. . . Angelo, I understood every word that you said — CPR and breathing machines, but I had no idea that is what you meant.”

I was reprimanded by the ICU staff for bringing Helen and her husband on that tour, but I was quickly forgiven. Evidently, many felt, like me, that patients deserve to be educated in order to make informed decisions about end-of-life choices.”

That was years ago when he was a medical resident.

Today, he goes on to explain, he and others use video decision aids to help people think about care options.


View the original article here

Friday, June 22, 2012

Prolactinoma: options for the treatment of pituitary gland tumor

By Mayo Clinic staff

Prolactinoma is a condition in which a usually noncancerous tumor (adenoma) in the pituitary gland in your brain overproduces prolactin hormone. The main effect of prolactin is a decrease in the levels of some hormones — estrogen in women and testosterone in men.


Although Prolactinoma is not life-threatening, can impair your vision, cause infertility and produce other effects. Prolactinoma is one of several types of cancer that can develop in your pituitary gland.


Doctors may treat Prolactinoma with medications often effectively to restore your prolactin level to normal. Surgery to remove the pituitary tumor, may also be an option for treating Prolactinoma.

References Prolactinoma. National Institute of diabetes and digestive and kidney diseases. http://endocrine.niddk.nih.gov/pubs/prolact/prolact.htm. Accessed on 17 January 2011., Melmed S, et al., diagnosis and treatment of hyperprolactinemia: clinical practice guideline of An Endocrine Society. The Journal of Clinical Endocrinology Metabolism &. 2011; 273.96: Colao, et al., the aggressive pituitary tumour therapy. Pharmacotherapy specialist opinion. 2011; 12: 1561. Mann WA. Treatment of prolactinomas and hyperprolactinaemia: a lifetime approach. European Journal of Clinical Investigation. 2011; 334.41: a. Klibanski Prolactinomas. The New England Journal of Medicine. 2010; 352: 121. Colao, et al. medical treatment of prolactinomas. Nature reviews Endocrinology. 2011; 7: 267.var shareUrl = encodeURIComponent (window.location); var shareTitle = encodeURIComponent (document.title);

Privacy Policy (updated August 2, 2011) terms and conditions of use policy (updated August 2, 2011)


LEGAL CONDITIONS AND TERMS OF USE APPLICABLE TO ALL USERS OF THIS SITE. ANY USE OF THIS SITE CONSTITUTES ACCEPTANCE OF THESE TERMS AND CONDITIONS OF USE.


© 1998-2012 Mayo Foundation for medical education and research.

Saturday, May 19, 2012

Prolactinoma: options for the treatment of pituitary gland tumor



By Mayo Clinic staff Prolactinoma is a condition in which a usually noncancerous tumor (adenoma) in the pituitary gland in your brain overproduces prolactin hormone. The main effect of prolactin is a decrease in the levels of some hormones — estrogen in women and testosterone in men.
Although Prolactinoma is not life-threatening, can impair your vision, cause infertility and produce other effects. Prolactinoma is one of several types of cancer that can develop in your pituitary gland.
Doctors may treat Prolactinoma with medications often effectively to restore your prolactin level to normal. Surgery to remove the pituitary tumor, may also be an option for treating Prolactinoma.
References Prolactinoma. National Institute of diabetes and digestive and kidney diseases. http://endocrine.niddk.nih.gov/pubs/prolact/prolact.htm. Accessed on 17 January 2011., Melmed S, et al., diagnosis and treatment of hyperprolactinemia: clinical practice guideline of An Endocrine Society. The Journal of Clinical Endocrinology Metabolism &. 2011; 273.96: Colao, et al., the aggressive pituitary tumour therapy. Pharmacotherapy specialist opinion. 2011; 12: 1561. Mann WA. Treatment of prolactinomas and hyperprolactinaemia: a lifetime approach. European Journal of Clinical Investigation. 2011; 334.41: a. Klibanski Prolactinomas. The New England Journal of Medicine. 2010; 352: 121. Colao, et al. medical treatment of prolactinomas. Nature reviews Endocrinology. 2011; 7: 267.var shareUrl = encodeURIComponent (window.location); var shareTitle = encodeURIComponent (document.title);
Privacy Policy (updated August 2, 2011) terms and conditions of use policy (updated August 2, 2011)
LEGAL CONDITIONS AND TERMS OF USE APPLICABLE TO ALL USERS OF THIS SITE. ANY USE OF THIS SITE CONSTITUTES ACCEPTANCE OF THESE TERMS AND CONDITIONS OF USE.
© 1998-2012 Mayo Foundation for medical education and research. 

Followers